Stephen  Gordon net worth and biography

Stephen Gordon Biography and Net Worth

Stephen Gordon joined TransMedics in March of 2015 and leads our finance and accounting team. He has over 20 years of experience leading financial organizations within high technology and medical device companies.  During this time his areas of focus have been strategic planning, M&A integration, financial planning and analysis, and improvement in the presentation of quantitative information. Prior to joining TransMedics, Mr. Gordon was the Vice President, Financial Planning & Analysis at Analogic Corporation, a medical device and security technology company. Before joining Analogic, Mr. Gordon held various financial leadership positions at Hologic, Cytyc, Maxtor and Hewlett-Packard. Mr. Gordon earned a Bachelor’s degree in Finance and Accounting from The Wharton School at The University of Pennsylvania, and an MBA from Boston University.

What is Stephen Gordon's net worth?

The estimated net worth of Stephen Gordon is at least $2.11 million as of April 1st, 2024. Mr. Gordon owns 23,299 shares of TransMedics Group stock worth more than $2,110,889 as of April 24th. This net worth approximation does not reflect any other assets that Mr. Gordon may own. Additionally, Mr. Gordon receives a salary of $909,620.00 as CFO at TransMedics Group. Learn More about Stephen Gordon's net worth.

How old is Stephen Gordon?

Mr. Gordon is currently 56 years old. Learn More on Stephen Gordon's age.

What is Stephen Gordon's salary?

As the CFO of TransMedics Group, Inc., Mr. Gordon earns $909,620.00 per year. The highest earning executive at TransMedics Group is Dr. Waleed H. Hassanein M.D., Founder, President, CEO & Director, who commands a salary of $1,820,000.00 per year. Learn More on Stephen Gordon's salary.

How do I contact Stephen Gordon?

The corporate mailing address for Mr. Gordon and other TransMedics Group executives is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. TransMedics Group can also be reached via phone at (978) 552-0900 and via email at [email protected]. Learn More on Stephen Gordon's contact information.

Has Stephen Gordon been buying or selling shares of TransMedics Group?

In the last ninety days, Stephen Gordon has sold $1,110,150.00 of TransMedics Group stock. Most recently, Stephen Gordon sold 15,000 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $74.01, for a transaction totalling $1,110,150.00. Following the completion of the sale, the chief financial officer now directly owns 23,299 shares of the company's stock, valued at $1,724,358.99. Learn More on Stephen Gordon's trading history.

Who are TransMedics Group's active insiders?

TransMedics Group's insider roster includes John Carey (VP), Laura Damme (VP), Stephen Gordon (CFO), Waleed Hassanein (CEO), Edwin Kania, Jr. (Director), Tamer Khayal (Insider), and Miriam Provost (VP). Learn More on TransMedics Group's active insiders.

Are insiders buying or selling shares of TransMedics Group?

In the last year, TransMedics Group insiders bought shares 1 times. They purchased a total of 2,500 shares worth more than $155,000.00. In the last year, insiders at the sold shares 31 times. They sold a total of 231,712 shares worth more than $18,661,937.87. The most recent insider tranaction occured on April, 17th when CEO Waleed H Hassanein sold 4,000 shares worth more than $380,480.00. Insiders at TransMedics Group own 6.7% of the company. Learn More about insider trades at TransMedics Group.

Information on this page was last updated on 4/17/2024.

Stephen Gordon Insider Trading History at TransMedics Group

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/1/2024Sell15,000$74.01$1,110,150.0023,299View SEC Filing Icon  
3/8/2024Sell1,903$87.63$166,759.8923,299View SEC Filing Icon  
3/4/2024Sell15,000$82.80$1,242,000.0025,202View SEC Filing Icon  
2/1/2024Sell15,000$85.45$1,281,750.0013,075View SEC Filing Icon  
1/2/2024Sell15,000$77.07$1,156,050.0013,075View SEC Filing Icon  
10/2/2023Sell5,000$54.22$271,100.0018,789View SEC Filing Icon  
5/1/2023Sell5,000$79.05$395,250.0018,789View SEC Filing Icon  
3/1/2023Sell5,000$79.51$397,550.0018,789View SEC Filing Icon  
1/17/2023Sell5,000$60.12$300,600.005,714View SEC Filing Icon  
11/7/2022Sell10,000$56.72$567,200.005,714View SEC Filing Icon  
10/3/2022Sell10,000$41.74$417,400.005,714View SEC Filing Icon  
7/5/2022Sell10,000$35.00$350,000.005,714View SEC Filing Icon  
9/7/2021Sell10,000$35.00$350,000.0015,714View SEC Filing Icon  
7/15/2021Sell10,000$35.00$350,000.0015,714View SEC Filing Icon  
6/17/2021Sell10,000$30.00$300,000.0010,000View SEC Filing Icon  
3/15/2021Sell10,000$39.81$398,100.0010,000View SEC Filing Icon  
2/16/2021Sell10,000$31.33$313,300.0010,000View SEC Filing Icon  
2/8/2021Sell10,000$25.01$250,100.00View SEC Filing Icon  
1/4/2021Sell10,000$20.00$200,000.00
4/27/2020Sell9,900$18.00$178,200.0018,571View SEC Filing Icon  
4/22/2020Sell100$18.00$1,800.0028,471View SEC Filing Icon  
See Full Table

Stephen Gordon Buying and Selling Activity at TransMedics Group

This chart shows Stephen Gordon's buying and selling at TransMedics Group by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

TransMedics Group Company Overview

TransMedics Group logo
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Read More

Today's Range

Now: $87.24
Low: $86.59
High: $90.97

50 Day Range

MA: $82.95
Low: $70.86
High: $95.65

2 Week Range

Now: $87.24
Low: $36.42
High: $99.63

Volume

329,000 shs

Average Volume

685,347 shs

Market Capitalization

$2.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99